## LIST OF FIGURES


| | | |
|---|---|---|
| Figure 2.1 | Methods for the preparation of mPEG- phosphatidyl ethanolamine conjugates | 57 |
| Figure 2.2 | Synthesis of hydrazone-linked mPEG-lipid | 58 |
| Figure 2.3 | End group functionalized PEG lipids | 61 |
| Figure 2.4 | Amphiphilic synthetic polymers used for steric protection of liposomes | 62 |
| Figure 3.1 | Absorptivity scan of methotrexate in methanol | 124 |
| Figure 3.2 | Absorptivity scan of tamoxifen citrate in methanol | 127 |
| Figure 3.3 | Absorptivity scan of cytarabine in methanol | 130 |
| Figure 3.4 | Absorptivity scan of methotrexate in PBS | 133 |
| Figure 3.5 | Absorptivity scan of tamoxifen citrate in PBS | 133 |
| Figure 3.6 | Absorptivity scan of cytarabine in PBS | 138 |
| Figure 4.1 | Flowchart for the preparation of conventional liposomes containing methotrexate | 167 |
| Figure 4.2 | Results of electrolyte induced flocculation test on conventional liposomes containing methotrexate | 168 |
| Figure 4.3 | Flowchart for the preparation of conventional liposomes containing tamoxifen citrate | 171 |
| Figure 4.4 | Results of electrolyte induced flocculation test on conventional liposomes containing tamoxifen citrate | 172 |
| Figure 4.5 | Flowchart for the preparation of conventional liposomes containing cytarabine | 176 |
| Figure 4.6 | Results of electrolyte induced flocculation test on conventional liposomes containing cytarabine | 177 |
| Figure 4.7 | Ultraviolet absorptivity scan of cyanuric chloride (CC) in methanol (1mg/ml) | 181 |
| Figure 4.8 | Ultraviolet absorptivity scan of methoxy polyethylene glycol 5000 (mPEG5000) in methanol (1mg/ml) | 182 |
| Figure 4.9 | Ultraviolet absorptivity scan of methoxy polyethylene glycol 5000 activated with cyanuric chloride (mPEG5000-CC) in methanol (1mg/ml) | 182 |
| Figure 4.10 | Mid infra-red spectrum of methoxy polyethylene glycol 5000 activated with cyanuric chloride (mPEG5000-CC) | 183 |
| Figure 4.11 | $^{13}$C-NMR spectrum of methoxy polyethylene glycol 5000 activated with cyanuric chloride (mPEG5000-CC) | 184 |
| Figure 4.12 | Reaction scheme for the synthesis of methoxy polyethylene glycol 5000 activated with cyanuric chloride-phosphatidylethanolamine conjugate (mPEG5000-CC-PE) | 185 |
| Figure 4.13 | Ultraviolet absorptivity scan of Phosphatidyl ethanolamine (PE) in methanol (1mg/ml) | 186 |
| Figure 4.14 | Ultraviolet absorptivity scan of methoxy polyethylene glycol 5000 activated with cyanuric chloride –phosphatidyl ethanolamine conjugate (mPEG5000-CC-PE) in methanol (5mg/ml) | 186 |

| | | |
|---|---|---|
| Figure 4.15 | Mid infra-red spectrum of methoxy polyethylene glycol 5000 activated with cyanuric chloride – phosphatidyl ethanolamine conjugate (mPEG5000-CC-PE) | 187 |
| Figure 4.16 | $^{13}$C-NMR spectrum of methoxy polyethylene glycol 5000 activated with cyanuric chloride – phosphatidyl ethanolamine conjugate (mPEG5000-CC-PE) | 188 |
| Figure 4.17 | Flowchart for the preparation of sterically stabilized liposomes containing methotrexate using methoxy polyethylene glycol 5000 activated with cyanuric chloride – phosphatidyl ethanolamine conjugate (mPEG5000-CC-PE) | 189 |
| Figure 4.18 | Optimization of mPEG5000-CC-PE concentration, required for steric stabilization of methotrexate containing liposomes, using electrolyte induced flocculation test | 190 |
| Figure 4.19 | Flowchart for the preparation of sterically stabilized liposomes containing tamoxifen citrate using methoxy polyethylene glycol 5000 activated with cyanuric chloride-phosphatidyl ethanolamine conjugate (mPEG5000-CC-PE) | 191 |
| Figure 4.20 | Optimization of mPEG5000-CC-PE concentration, required for steric stabilization of tamoxifen citrate containing liposomes, using electrolyte induced flocculation test | 192 |
| Figure 4.21 | Flowchart for the preparation of sterically stabilized liposomes containing cytarabine using methoxy polyethylene glycol 5000 activated with cyanuric chloride – phosphatidyl ethanolamine conjugate (mPEG5000-CC-PE) | 193 |
| Figure 4.22 | Optimization of mPEG5000-CC-PE concentration, required for steric stabilization of cytarabine containing liposomes, using electrolyte induced flocculation test | 194 |
| Figure 4.23 | Ultraviolet absorptivity scan of methoxy polyethylene glycol 2000 in methanol (1mg/ml) | 197 |
| Figure 4.24 | Ultraviolet absorptivity scan of methoxy polyethylene glycol 2000 activated with cyanuric chloride (mPEG2000-CC) in methanol (1mg/ml) | 197 |
| Figure 4.25 | Mid infra-red spectrum of methoxy polyethylene glycol 2000 activated with cyanuric chloride (mPEG2000-CC) in methanol | 198 |
| Figure 4.26 | Reaction scheme of synthesis of methoxy polyethylene glycol 2000 activated with cyanuric chloride - phosphatidyl ethanolamine conjugate (mPEG2000-CC-PE) | 199 |
| Figure 4.27 | Ultraviolet absorptivity scan of methoxy polyethylene glycol 2000 coupled with cyanuric chloride – phosphatidyl ethanolamine conjugate (mPEG2000-CC-PE) in methanol (1mg/ml) | 200 |
| Figure 4.28 | Mid infra-red spectrum of methoxy polyethylene glycol 2000 activated with cyanuric chloride – phosphatidyl ethanolamine conjugate (mPEG2000-CC-PE) | 201 |
| Figure 4.29 | $^{13}$C-NMR spectrum of methoxy polyethylene glycol 2000 activated with cyanuric chloride – phosphatidyl ethanolamine conjugate (mPEG2000-CC-PE) | 202 |

| | | |
|---|---|---|
| Figure 4.30 | Flowchart for the preparation of sterically stabilized liposomes containing methotrexate using methoxy polyethylene glycol 2000 activated with cyanuric chloride-phosphatidylethanolamine conjugate (mPEG2000-CC-PE) | 203 |
| Figure 4.31 | Optimization of mPEG2000-CC-PE concentration, required for steric stabilization of methotrexate containing liposomes, using electrolyte induced flocculation test | 204 |
| Figure 4.32 | Flowchart for the preparation of sterically stabilized liposomes containing tamoxifen citrate using methoxy polyethylene glycol 2000 activated with cyanuric chloride-phosphatidylethanolamine conjugate (mPEG2000-CC-PE) | 205 |
| Figure 4.33 | Optimization of mPEG2000-CC-PE concentration, required for steric stabilization of tamoxifen citrate containing liposomes, using electrolyte induced flocculation test | 206 |
| Figure 4.34 | Flowchart for the preparation of sterically stabilized liposomes containing cytarabine using methoxy polyethylene glycol 2000 activated with cyanuric chloride-phosphatidyl ethanolamine conjugate (mPEG2000-CC-PE) | 207 |
| Figure 4.35 | Optimization of mPEG2000-CC-PE concentration, required for steric stabilization of cytarabine containing liposomes, using electrolyte induced flocculation test | 208 |
| Figure 4.36 | Ultraviolet absorptivity scan of methoxy polyethylene glycol 5000 activated with imidazoline carbonyl (mPEG5000-IC) in methanol (1mg/ml) | 211 |
| Figure 4.37 | Ultraviolet absorptivity scan of methoxy polyethylene glycol 5000 activated with imidazoline carbonyl –phosphatidyl ethanolamine conjugate (mPEG5000-IC-PE) in methanol (1mg/ml) | 211 |
| Figure 4.38 | Mid infra-red spectrum of methoxy polyethylene glycol 5000 activated with imidazoline carbonyl (mPEG5000-IC) | 212 |
| Figure 4.39 | Mid infra-red spectrum of methoxy polyethylene glycol 2000 activated with imidazoline carbonyl – phosphatidyl ethanolamine conjugate (mPEG5000-IC-PE) | 213 |
| Figure 4.40 | $^{13}$C-NMR spectrum of methoxy polyethylene glycol 5000 activated with imidazoline carbonyl – phosphatidyl ethanolamine conjugate (mPEG5000-IC-PE) | 214 |
| Figure 4.41 | Reaction scheme for synthesis of methoxy polyethylene glycol 5000 activated with imidazoline carbonyl and coupled with phosphatidylethanolamine conjugate (mPEG5000-IC-PE) | 215 |
| Figure 4.42 | Flowchart for the preparation of sterically stabilized liposomes containing methotrexate using methoxy polyethylene glycol 5000 activated with imidazoline carbonyl –phosphatidyl ethanolamine conjugate (mPEG5000-IC-PE) | 216 |
| Figure 4.43 | Optimization of mPEG5000-IC-PE concentration, required for steric stabilization of methotrexate containing liposomes, using electrolyte induced flocculation test | 217 |

| | | |
|---|---|---|
| Figure 4.44 | Flowchart for the preparation of sterically stabilized liposomes containing tamoxifen citrate using methoxy polyethylene glycol 5000 activated with imidazoline carbonyl -phosphatidylethanolamine conjugate (mPEG5000-IC-PE) | 218 |
| Figure 4.45 | Optimization of mPEG5000-IC-PE concentration, required for steric stabilization of tamoxifen citrate containing liposomes, using electrolyte induced flocculation test | 219 |
| Figure 4.46 | Flowchart for the preparation of sterically stabilized liposomes containing cytarabine using methoxy polyethylene glycol 5000 activated with imidazoline carbonyl-phosphatidyl ethanolamine conjugate (mPEG5000-IC-PE) | 220 |
| Figure 4.47 | Optimization of mPEG5000-IC-PE concentration, required for steric stabilization of cytarabine containing liposomes, using electrolyte induced flocculation test | 221 |
| Figure 5.1 | Photomicrograph of conventional liposomes containing methotrexate | 244 |
| Figure 5.2 | Photomicrograph of liposomes containing methotrexate sterically stabilized using methoxy polyethylene glycol 5000 – activated with cyanuric chloride-phosphatidyl ethanolamine conjugate | 244 |
| Figure 5.3 | Photomicrograph of liposomes containing methotrexate sterically stabilized using methoxy polyethylene glycol 2000 – activated with cyanuric chloride-phosphatidyl ethanolamine conjugate | 245 |
| Figure 5.4 | Photomicrograph of liposomes containing methotrexate sterically stabilized using methoxy polyethylene glycol 5000 – activated with imidazoline carbonyl phosphatidyl ethanolamine conjugate | 245 |
| Figure 5.5 | Photomicrograph of conventional liposomes containing tamoxifen citrate | 246 |
| Figure 5.6 | Photomicrograph of liposomes containing tamoxifen citrate sterically stabilized using methoxy polyethylene glycol 5000 – activated with cyanuric chloride - phosphatidyl ethanolamine conjugate | 246 |
| Figure 5.7 | Photomicrograph of liposomes containing tamoxifen citrate sterically stabilized using methoxy polyethylene glycol 2000 – activated with cyanuric chloride - phosphatidyl ethanolamine conjugate | 247 |
| Figure 5.8 | Photomicrograph of liposomes containing tamoxifen citrate sterically stabilized using methoxy polyethylene glycol 5000 – activated with imidazoline carbonyl - phosphatidyl ethanolamine conjugate | 247 |
| Figure 5.9 | Photomicrograph of conventional liposomes containing cytarabine | 248 |
| Figure 5.10 | Photomicrograph of liposomes containing cytarabine sterically stabilized using methoxy polyethylene glycol 5000 – activated with cyanuric chloride - phosphatidyl ethanolamine conjugate | 248 |

| | | |
|---|---|---|
| Figure 5.11 | Photomicrograph of liposomes containing cytarabine sterically stabilized using methoxy polyethylene glycol 2000 – activated with cyanuric chloride - phosphatidyl ethanolamine conjugate | 249 |
| Figure 5.12 | Photomicrograph of liposomes containing cytarabine sterically stabilized using methoxy polyethylene glycol 5000 – activated with imidazoline carbonyl - phosphatidyl ethanolamine conjugate | 249 |
| Figure 5.13 | Scanning electron micrograph of conventional liposomes containing methotrexate | 250 |
| Figure 5.14 | Scanning electron micrograph of liposomes containing methotrexate sterically stabilized using mPEG5000-CC-PE | 250 |
| Figure 5.15 | Scanning electron micrograph of conventional liposomes containing tamoxifen citrate sterically stabilized using mPEG2000-CC-PE | 250 |
| Figure 5.16 | Scanning electron micrograph of conventional liposomes containing cytarabine | 251 |
| Figure 5.17 | Scanning electron micrograph of conventional liposomes containing cytarabine sterically stabilized using mPEG5000-IC-PE | 251 |
| Figure 5.18 | DSC thermogram of conventional liposomes containing methotrexate | 252 |
| Figure 5.19 | DSC thermogram of liposomes containing methotrexate sterically stabilized using methoxy polyethylene glycol 5000 – activated with cyanuric chloride – phosphatidyl ethanolamine conjugate (mPEG5000-CC-PE) | 253 |
| Figure 5.20 | DSC thermogram of conventional liposomes containing tamoxifen citrate | 254 |
| Figure 5.21 | DSC thermogram of liposomes containing tamoxifen citrate sterically stabilized using methoxy polyethylene glycol 2000 – activated with cyanuric chloride – phosphatidyl ethanolamine conjugate (mPEG2000-CC-PE) | 255 |
| Figure 5.22 | DSC thermogram of conventional liposomes containing cytarabine | 256 |
| Figure 5.23 | DSC thermogram of liposomes containing cytarabine sterically stabilized using methoxy polyethylene glycol 5000 – activated with cyanuric chloride – phosphatidyl ethanolamine conjugate (mPEG5000-CC-PE) | 257 |
| Figure 5.24 | DSC thermogram of liposomes containing cytarabine sterically stabilized using methoxy polyethylene glycol 2000 – activated with cyanuric chloride – phosphatidyl ethanolamine conjugate (mPEG2000- CC-PE) | 258 |
| Figure 5.25 | DSC thermogram of liposomes containing cytarabine sterically stabilized using methoxy polyethylene glycol 5000 – activated with imidazoline carbonyl – phosphatidyl ethanolamine conjugate (mPEG5000-IC-PE) | 259 |
| Figure 5.26 | Photograph of electrophoresis studies carried out on liposomes containing methotrexate | 260 |

| | | |
|---|---|---|
| Figure 5.27 | Photograph of electrophoresis studies carried out on liposomes containing tamoxifen citrate | 260 |
| Figure 5.28 | Photograph of electrophoresis studies carried out on liposomes containing cytarabine | 261 |
| Figure 6.1 | *In vitro* drug release studies of conventional liposomes of methotrexate | 281 |
| Figure 6.2 | *In vitro* drug release studies of liposomes containing methotrexate sterically stabilized with mPEG5000-CC-PE | 281 |
| Figure 6.3 | *In vitro* drug release studies of liposomes containing methotrexate sterically stabilized with mPEG2000-CC-PE | 282 |
| Figure 6.4 | *In vitro* drug release studies of liposomes containing methotrexate sterically stabilized with mPEG5000-IC-PE | 282 |
| Figure 6.5 | *In vitro* drug release studies of conventional liposomes of tamoxifen citrate | 283 |
| Figure 6.6 | *In vitro* drug release studies of liposomes containing tamoxifen citrate sterically stabilized with mPEG5000-CC-PE | 283 |
| Figure 6.7 | *In vitro* drug release studies of liposomes containing tamoxifen citrate sterically stabilized with mPEG2000-CC-PE | 284 |
| Figure 6.8 | *In vitro* drug release studies of liposomes containing tamoxifen citrate sterically stabilized with mPEG5000-IC-PE | 284 |
| Figure 6.9 | *In vitro* drug release studies of conventional liposomes of cytarabine | 285 |
| Figure 6.10 | *In vitro* drug release studies of liposomes containing cytarabine sterically stabilized with mPEG5000-CC-PE | 285 |
| Figure 6.11 | *In vitro* drug release studies of liposomes containing cytarabine sterically stabilized mPEG2000-CC-PE | 286 |
| Figure 6.12 | *In vitro* drug release studies of liposomes containing cytarabine sterically stabilized with mPEG5000-IC-PE | 286 |
| Figure 7.1 | Effect of different ratios of cryoprotectants on efficiency of lyophilization of liposomal formulation. | 304 |
| Figure 8.1 | Time dependent *in vitro* cytotoxicity study of methotrexate | 318 |
| Figure 8.2 | *In vitro* cytotoxicity study of methotrexate and its liposomes | 319 |
| Figure 8.3 | Time dependent *in vitro* cytotoxicity study of tamoxifen citrate | 320 |
| Figure 8.4 | *In vitro* cytotoxicity study of tamoxifen citrate and its liposomes | 321 |
| Figure 8.5 | Time dependent *in vitro* cytotoxicity study of cytarabine | 321 |
| Figure 8.6 | *In vitro* cytotoxicity study of cytarabine and its liposomes | 322 |
| Figure 9.1 | Effect of pH on radiolabeling efficiency of MTX and its liposomal formulations | 334 |
| Figure 9.2 | Effect of incubation time on radiolabeling efficiency of MTX and its liposomal formulations | 335 |
| Figure 9.3 | DTPA challenging test of MTX and its liposomal formulations | 338 |

| | | |
|---|---|---|
| Figure 9.4 | Effect of pH on radiolabeling efficiency of TMX and its liposomal formulations | 340 |
| Figure 9.5 | Effect of incubation time on radiolabeling efficiency of TMX and its liposomal formulations | 341 |
| Figure 9.6 | DTPA challenging test of TMX and its liposomal formulations | 344 |
| Figure 9.7 | Effect of pH on radiolabeling efficiency of CYT and its liposomal formulations | 346 |
| Figure 9.8 | Effect of incubation time on radiolabeling efficiency of CYT and its liposomal formulations | 347 |
| Figure 9.9 | DTPA challenging test of CYT and its liposomal formulations | 350 |
| Figure 10.1 | Blood kinetic study of $^{99m}$Tc labeled methotrexate and its liposomes | 364 |
| Figure 10.2 | Blood kinetic study of $^{99m}$Tc labeled tamoxifen citrate and its liposomes | 367 |
| Figure 10.3 | Blood kinetic study of $^{99m}$Tc labeled cytarabine and its liposomes | 370 |
| Figure 10.4 | Tissue uptake ratio of various organs of the $^{99m}$Tc labeled methotrexate and its liposomes | 374 |
| Figure 10.5 | Tissue uptake ratio of various organs of the $^{99m}$Tc labeled tamoxifen citrate and its liposomes | 377 |
| Figure 10.6 | Tissue uptake ratio of various organs of the $^{99m}$Tc labeled cytarabine and its liposomes | 380 |
| Figure 10.7 | Gamma scintigraphic image of $^{99m}$Tc - MTX injected mouse bearing EAT in the left thigh. | 383 |
| Figure 10.8 | Gamma scintigraphic image of $^{99m}$Tc - ML injected mouse bearing EAT in the left thigh | 383 |
| Figure 10.9 | Gamma scintigraphic image of $^{99m}$Tc - SML5000-CC-PE injected mouse bearing EAT in the left thigh | 384 |
| Figure 10.10 | Gamma scintigraphic image of $^{99m}$Tc - SML2000-CC-PE injected mouse bearing EAT in the left thigh | 384 |
| Figure 10.11 | Gamma scintigraphic image of $^{99m}$Tc - SML5000-IC-PE injected mouse bearing EAT in the left thigh | 385 |
| Figure 10.12 | Gamma scintigraphic image of $^{99m}$Tc - TMX injected mouse bearing EAT in the left thigh | 385 |
| Figure 10.13 | Gamma scintigraphic image of $^{99m}$Tc - TL injected mouse bearing EAT in the left thigh | 386 |
| Figure10.14 | Gamma scintigraphic image of $^{99m}$Tc - STL5000-CC-PE injected mouse bearing EAT in the left thigh | 386 |
| Figure 10.15 | Gamma scintigraphic image of $^{99m}$Tc - STL2000-CC-PE injected mouse bearing EAT in the left thigh | 387 |
| Figure 10.16 | Gamma scintigraphic image of $^{99m}$Tc - STL5000-IC-PE injected mouse bearing EAT in the left thigh | 387 |
| Figure 10.17 | Gamma scintigraphic image of $^{99m}$Tc - CYT injected mouse bearing EAT in the left thigh | 388 |

Figure 10.18 Gamma scintigraphic image of $^{99m}$Tc - CL injected mouse bearing EAT in the left thigh 388
Figure 10.19 Gamma scintigraphic image of $^{99m}$Tc - SCL5000-CC-PE injected mouse bearing EAT in the left thigh 389
Figure 10.20 Gamma scintigraphic image of $^{99m}$Tc - SCL2000-CC-PE injected mouse bearing EAT in the left thigh 389
Figure10.21 Gamma scintigraphic image of $^{99m}$Tc - SCL5000-IC-PE injected mouse bearing EAT in the left thigh 390